FDA approval this week of the Emblem S-ICD made by Boston Scientific (NYSE:BSX) puts the company in place to take market share in the cardiac rhythm management space from rivals St. Jude Medical (NYSE:STJ) and Medtronic (NYSE:MDT), Wells Fargo analysts said.
Revenues from St. Jude’s CardioMEMS device, which that company is counting on, won’t be enough to offset the share losses from Boston’s Emblem device, the analysts wrote in a note to investors.
Help employers find you! Check out all the jobs and post your resume.
